Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis
Markus V. Heppt(Universitätsklinikum Erlangen), Carola Berking(Universitätsklinikum Erlangen), Rudolf Herbst(Helios Klinikum Erfurt), Susanne G. Schäd(University of Rostock), Julia K. Tietze(LMU Klinikum), Daniela Göppner(Universitätsklinikum Gießen und Marburg), Katharina C. Kähler(Christian-Albrechts-Universität zu Kiel), Erwin Schultz(Nuremberg Hospital), Thilo Gambichler(Witten/Herdecke University), Thomas Eigentler(University Children's Hospital Tübingen), Fanny Matheis(Hinge Health), Carmen Loquai(Johannes Gutenberg University Mainz), Bastian Schilling(Goethe University Frankfurt), Beatrice Schell(SRH Wald-Klinikum Gera), Edgar Dippel(Klinikum Ludwigshafen)
Cited by 81
Related Papers
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
|Science|2016|3.1k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
|Cell|2018|1.5k
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k